Transplanting lungs from donors after circulatory death

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates a protocol for transplanting lungs from uncontrolled donors after circulatory death (uDCD). It involves preserving lungs for over three hours post-death using positive end-expiratory pressure (PEEP) and supplemental oxygen. The safety of the uDCD program will be assessed through continuous review of clinical records and operational data, focusing on lung preservation rates, recovery, and transplantation outcomes. Viability assessments will include macroscopic evaluations, radiology, and bronchoscopy prior to ex-vivo lung perfusion (EVLP). The study aims to achieve a transplantation rate of approximately 50% for lungs assessed with EVLP.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients waiting for lung transplants
* Willing to participate in the research study

Exclusion Criteria:

* Unable to be followed for 1 year after transplantation
* Unable to provide written informed consent to participate in the research (or designate a surrogate)

Where it's running

• NYU Langone Health
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Stephen Wall, MD — NYU Langone Health
• Study coordinator: Carolyn Sidoti
• Email: Carolyn.Sidoti@nyulangone.org
• Phone: 646-987-1371

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Muscle health before and after lung transplant in adults

  This study tests how respiratory and leg muscle health relates to physical function and recovery in adults awaiting and after lung transplantation.

  Recruiting University of Florida · Gainesville, Florida · NCT07747337

• Prediction score for death or lung transplant in emphysema caused by alpha-1 antitrypsin deficiency

  This study tests a new prediction tool to identify people with emphysema due to alpha-1-antitrypsin deficiency who are at high risk of death or needing a lung transplant.

  Recruiting at 4 sites University Hospital, Bordeaux · Bron and 3 other locations · NCT07715617

• Long-term health of children born to mothers who had a solid organ transplant

  This project will look for long-term heart, kidney, and immune system problems in people aged 16 and older who were born to mothers who had a kidney, liver, pancreas, heart, or lung transplant.

  Recruiting University Medical Center Groningen · Groningen, Provincie Groningen · NCT07291258

• Aerobic versus high-intensity interval exercise for people awaiting lung transplant

  This trial tests whether short bursts of high-intensity interval training or longer moderate aerobic sessions better improve walking distance and daily function for people with interstitial lung disease who are on the lung transplant waiting list.

  Recruiting Ankara City Hospital Bilkent · Ankara · NCT07065318

• Tacrolimus Melt-Dose® for people after a lung transplant

  This study will test how a once-daily Melt-Dose® tacrolimus (LCPT) is processed in the body and how safe it is for adults who recently had a unilateral or bilateral lung transplant over 12 months.

  Recruiting at 2 sites Chiesi España, S.A.U. · L'Hospitalet de Llobregat, Barcelona and 1 other locations · NCT07042035

• Fostamatinib to see if it’s safe for lung transplant patients with donor-specific antibodies

  This trial tests whether taking fostamatinib is safe for adults who have donor-specific antibodies after a lung transplant.

  Recruiting at 4 sites Phase 1 National Institutes of Health Clinical Center (CC) · Stanford, California and 3 other locations · NCT06948097

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.